Stelexis Therapeutics

Developer of small molecules to target pre‐cancerous stem cells

placeNew York City, New York, United States calendar_todayFounded 2017 groups7 employees language stelexis.com

Innovation

3 patent families — focus: Chemistry & metallurgy; filing pace accelerating. Cited 49 times.

YearFilings
20221
20232
20243
20252

Social engagement

Social engagement: 952 social following, 1 post in the last 12 months — below the industry typical range.

Coming soon